Journal

What TrainLoop's NollaMD visual-medicine results suggest about specialist AI, and why a benchmark cannot validate an autonomous prescribing service.

Nolla Health's acne pilot raises practical questions about assessment, contraindications, follow-up and the evidence needed for safe AI prescribing.

Compare Nolla Health's initial acne-treatment pilot with Doctronic's prescription-renewal pilot, focusing on scope, oversight and meaningful evidence.

What Nolla Health's Utah acne pilot permits, how physician oversight works, and why initial AI prescriptions are not unrestricted medical practice.

Heidi Work needs adoption measures that distinguish quiet, reliable task completion from abandonment, repeated checking and rescue work.

Compare TORTUS documentation and iatroX reference and learning, with an October 2026 distinction for the separate patient-facing TORTUS Health service.

A hypothetical £30 million TORTUS Series A would matter through product, evidence and implementation milestones, not through a cross-currency funding league table.

TORTUS Data Insights raises a clinical audit opportunity, but structured notes must not be mistaken for proof of completed care or improved outcomes.

TORTUS Health adds a patient-facing care model to the earlier competitive scenarios, changing the questions Heidi, Tandem and clinical AI buyers should ask.

TORTUS offers an outcomes-linked hospital partnership model, but credible value depends on separating time, capacity and cash with transparent measurement.

TORTUS SDK partnerships suggest an embedded distribution strategy, with opportunities in workflow access and trade-offs in control, support and economics.

Tandem teleQ in Sweden and TORTUS within X-on illustrate different routes into telephone workflows, where reliable post-call completion could matter most.